Design and Evaluation of Gastroretentive Ranitidine HCL Sustained Release Bilayer Tablet Using Wax Matrix: A Recent Study
Background: This paper describes a study of floating bilayer tablets of Ranitidine HCl, an H2 receptor antagonist used to treat peptic ulcers. Ranitidine HCl has a 50 percent absolute bioavailability and is consumed only in the first portion of the small intestine.
The gas-releasing portion, which is required for the tablet to float, is added to the food-grade rice bran wax matrix layer, while the delayed release component, HPMC K100M, is added to a separate layer of the bi-layer matrix tablet. The properties of the granulated powder blends were assessed using Carr’s Index and Hausner’s ratio before being compressed into a bilayer tablet. The tablets were tested for drug content, buoyancy lag time, buoyancy time, dissolution rate, and drug dissolution kinetics.
The tablet became buoyant as a result of the gas released. With an increase in the amount of rice bran wax in the floating part layer, the buoyancy lag time decreased. This layer slowly erodes, holding the tablet afloat for nearly 6 hours. The drug is released from the HPMC K100M matrix after a nearly 10-hour wait.
Conclusion: The HPMC K100M concentration used in the delayed release part layer has the potential to be mucoadhesive. As the floating component layer erodes away from the delayed release component layer’s swollen matrix, the swollen matrix’s mucoadhesive nature allows the tablet to remain confined to the upper GIT, where the drug has a preferential absorption location. This would increase the drug’s bioavailability.
Author (s) Details
Dr. A. H. Deshpande
Department of Pharmaceutics, Gurunanak College of Pharmacy, Nagpur, India.
Dr. D. D. Wasule
Lady Amritabai Daga for Women of Arts, Commerce and Science and Smt. Ratnidevi Purohit College of Homescience and Homescience Technology, Nagpur, India.
View Book :- https://stm.bookpi.org/HMMR-V6/article/view/627